रैंकिंग पर वापस जाएं

Resmed Inc (RMD)

Undervalued
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

75

मूल्य

$223.58

मार्केट कैप

$32.04B

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

बैलेंस शीट और तरलता

राजस्व

$5.65B

पिछले 12 महीने (30/6/2026 तक)

शुद्ध आय

$1.52B

पिछले 12 महीने (30/6/2026 तक)

Free Cash Flow

$1.65B

कुल इक्विटी

$6.59B

कुल देनदारियाँ

$2.38B

Current Ratio

3.10

Interest Coverage

-

Debt/EBITDA

0.40

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

सामान्य मामलाकम मूल्यांकित

Fair Value

$347.45

वर्तमान मूल्य

$223.58

Margin of Safety

+35.7%

Fair Value सीमा

$225.84 - $469.06

इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।

अनुमान विधियाँ

विश्लेषकों का लक्ष्य मूल्य:$250.22
डिस्काउंटेड कैश फ्लो (DCF):$650.15
आय गुणक (P/E):$187.86
Graham वृद्धि फॉर्मूला:$536.94
अर्निंग पावर वैल्यू (EPV):$117.55
उचित P/B:$95.10
लाभांश डिस्काउंट (Gordon):$35.11
P/FFO, परिचालन से प्राप्त निधि:$191.29
मध्य-चक्र आय:$184.44
राजस्व गुणक:$153.64
विश्लेषक सहमति:खरीदें (13B / 12H / 2S)
अंतिम Earnings सरप्राइज़:+1.09%

मूल्यांकन मेट्रिक्स

P/E Ratio

21.20

ROE

23.1%

P/B Ratio

4.84

P/FCF

19.34

Gross Margin

61.1%

ROIC

19.7%

लाभप्रदता Radar

मूल्य सृजन (प्रतिस्पर्धी बढ़त)

ROIC

19.7%

WACC

8.5%

ROIC − WACC

+11.2 pp

ROIC पूंजी की लागत से अधिक है — कंपनी शेयरधारकों के लिए मूल्य सृजित कर रही है।

Fundamental विश्लेषण मानदंड

पास (19)

  • EPS shows upward trend
  • EPS CAGR 15.14%
  • Price CAGR 13.41%
  • ROIC 19.7%
  • Gross Margin 61.1%
  • P/FCF 19.34
  • Debt/Equity ratio
  • Operating Margin 33.4%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 23.9%
  • Revenue Growth 5Y 12.1%
  • PEG Ratio 0.79
  • Earnings Quality (OCF/NI) 1.19
  • Share Dilution -0.8%
  • Piotroski F-Score 7/9

फेल (7)

  • P/B Ratio 4.84
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Analyst Consensus 48% Buy
  • Earnings Surprise avg 0.8%
  • Net Margin Trend 26.9% vs 27.2%

अनुपलब्ध (2)

  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-Score

7/9

मजबूत वित्तीय स्वास्थ्य

score
criteria

Earnings गुणवत्ता

1.19

उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित

शेयर Dilution

-0.8%

शेयर वापस खरीद रही है। शेयरधारक अनुकूल

संस्थागत होल्डिंग

प्रशासन

कार्यकारी टीम

नामपदआयु
Mr. Michael J. Farrell BE, MBA, SMCEO & Chairman53
Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScDFounder, Chair Emeritus & Non-Executive Director83
Mr. Michael J. RiderChief Legal Officer & Secretary67
Mr. Brett A. SandercockAdvisor58
Mr. Justin LeongChief Product Officer47
Mr. Aaron BloomerChief Financial Officer39
Mr. Alastair RobertsonChief Information Officer-
Ms. Sallilyn SchwartzChief Investor Relations Officer-
Mr. Jim EllisChief Compliance Officer-
Ms. Yvonne-Katrin PucknatChief Marketing Officer49

Audit जोखिम

1

बोर्ड जोखिम

7

मुआवजा जोखिम

4

शेयरधारक अधिकार जोखिम

3

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

दस्तावेज़

  • वार्षिक रिपोर्ट (10-K)

    कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।

    दाखिल तिथि: 2026-08-13

    दस्तावेज़ देखें
  • तिमाही रिपोर्ट (10-Q)

    पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।

    दाखिल तिथि: 2026-05-01

    दस्तावेज़ देखें
  • विशेष रिपोर्ट (8-K)

    किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।

    दाखिल तिथि: 2026-09-01

    दस्तावेज़ देखें

via SEC EDGAR

आय का इतिहास

via SEC EDGAR

Latest News

Recent headlines for RMD, sourced from Markets Gazette.

  • 3/10/2026POSITIVE
    3 Reasons Not to Sleep on ResMed Stock

    ResMed Inc., a prominent player in the sleep apnea and respiratory care market, is highlighted for its leadership in CPAP machines and other vital medical devices. The company's focus on improving respiratory health for millions globally positions it favorably within the healthcare sector. Investors are advised not to overlook ResMed's potential, suggesting a positive outlook driven by its established market position and ongoing innovation in medical technology. The company's products address a significant and growing health concern, underpinning its long-term value proposition.

  • 3/4/2026POSITIVE
    Here's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years

    ResMed Inc. (RMD) stock has delivered exceptional performance over the past 10 years, offering investors significant returns. While the article doesn't provide exact figures, the title "Here's How Much You Would Have Made" implies consistent and profitable growth. This is crucial for investors assessing the long-term potential of the medical device and sleep-care solutions sector. Past performance, while not guaranteeing future results, indicates ResMed's strong ability to generate shareholder value, potentially driven by product innovation, market expansion, and sound management.

via Markets Gazette

Disclaimer

यह प्लेटफ़ॉर्म केवल शैक्षिक उद्देश्यों के लिए है। यह कोई वित्तीय, निवेश, या ट्रेडिंग सलाह नहीं देता। सभी स्कोर, मूल्यांकन, और संकेत सार्वजनिक रूप से उपलब्ध डेटा के स्वचालित विश्लेषण पर आधारित हैं जो अधूरे या गलत हो सकते हैं। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और एक योग्य वित्तीय सलाहकार से परामर्श लें।

निर्मित द्वारा CODEPRESS s.r.l.